The performance of companies tied to flagship drugs like Viagra presents a complex investment scenario . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial wealth , the loss of exclusivity in key regions has introduced considerable risk . Investors are now grappling with the consequences of lower-co